Navigation Links
Smoking negatively affects response to anti-TNF treatment in patients with rheumatoid arthritis
Date:6/8/2012

Berlin, Germany, June 8 2012: A new study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, reinforces current thinking that smoking negatively affects treatment response in rheumatoid arthritis (RA) patients treated with anti-tumour necrosis factor (anti-TNF) drugs.

This American study, the largest of its kind, followed 2,811 treatment nave patients initiated onto anti-TNF therapy. Of the study group, 19% (n=521) were smokers and 81% (n=2,290) were non-smokers. Smokers had significantly higher scores on the Clinical Disease Activity Index (CDAI)* and DAS28** at six months than non-smokers. There was no significant difference in the odds of smokers versus non-smokers in achieving at least moderate EULAR*** response at six months and no difference in the change of mHAQ****.

Professor Ozlem Pala from the University of Miami Miller School of Medicine, USA and lead author of the study said: "There have been several studies which have investigated factors affecting response to anti-TNFs, but this is the first study to investigate response factors in such a large cohort of people. Being able to better predict response rates to treatment means that rheumatologists can discuss the findings with their patients who smoke and strongly encourage them to quit. This may also motivate them to develop successful strategies for smoking cessation in order to maximize effect of this expensive group of medications and potentially increase quality of life for these patients."

Disease activity measures at baseline were similar for DAS28 (approximately 3.7, standard deviation [SD]: 1.6) for both groups but higher for CDAI (17.1, SD: 13.8 vs 15.5, SD: 12.9) and mHAQ (0.5, SD: 0.5 vs 0.4, SD: 0.4) in smokers and non-smokers, respectively.

Patients were taken from the Consortium of Rheumatology Researchers of North America (CORRONA) registry. Mean duration of follow-up per patient was 3.4 years (SD: 2.6). Patients enrolled in the study were followed for up to 10.2 years. Biologic nave patients were followed for six months after initiation of an anti-TNF and outcomes of interest included DAS28, CDAI, mHAQ and EULAR response criteria after six months on therapy.


'/>"/>

Contact: Candice Debleu
eularpressoffice@cohnwolfe.com
44-789-438-6425
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Anti-tobacco TV ads help adults stop smoking, study finds
2. Exercise helps smokers to quit smoking, to remain smoke-free and to reduce the risk of death
3. Small neural focus groups predict anti-smoking ad success
4. Some women may be genetically predisposed to smoking-related hot flashes
5. Friends Parents Can Sway Teens Odds for Drinking, Smoking
6. Fewer Young Americans Smoking, Survey Finds
7. Vitamin C improves pulmonary function in newborns of pregnant smoking women
8. Genetic marker may predict smoking quantity in African Americans
9. 5 percent of workers gave up smoking when the anti-tobacco law took effect
10. Vitamin C improves lung function in newborns of pregnant smoking women
11. States Use Only Fraction of Tobacco Revenues to Fight Smoking, Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: